Motor and anxiety effects of PNU-282987, an alpha7 nicotinic receptor agonist, and stress in an animal model of Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 5, 2013, Pages 516-523

  Vicens, Paloma ^a   Ribes, Diana ^a   Heredia, Luis ^a   Torrente, Margarita ^a   Domingo, José L ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Alpha7 nicotinic receptors agonist; Anxiety; Motor activity; PNU 282987; Stress; Transgenic mice

Indexed keywords

4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE;

AGITATION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA; COGNITION; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DRUG EFFECT; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HOMEOSTASIS; MALE; MENTAL STRESS; MOTOR ACTIVITY; MOUSE; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TASK PERFORMANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BENZAMIDES; BICYCLO COMPOUNDS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; HUMANS; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; MOVEMENT DISORDERS; MUTATION; NICOTINIC AGONISTS; PRESENILIN-1; RESTRAINT, PHYSICAL;

EID: 84888230575     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990130     Document Type: Article

References (58)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, Uber eine eigenartige Erkankung der Hirnrinde. Clin Anat 8(6): 429-431 (1995).
2. McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 4(11):735-742 (2005).
3. Pinto T, Lanctot KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. Ageing Res Rev 10(4): 404-412 (2011).
4. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CPLH, Francis PT, Lasheras B, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43(3): 442-449 (2005).
5. D'Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Design 12(6): 677-684 (2006).
6. Mazurov A, Hauser T, Miller CH. Selective alpha 7 nicotinic acetylcholine receptor ligands. Curr Med Chem 13(13): 1567-1584 (2006).
7. Liu Q, Zhao B. Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. British journal of pharmacology 141(4): 746-754 (2004).
8. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharm 17(2): 145-155 (2007).
9. Kem WR. The brain alpha 7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 113(1-2): 169-181 (2000).
10. Carrasco C, Vicens P, Redolat R. Neuroprotective effects of behavioural training and nicotine on age-related deficits in spatial learning. Behav Pharmacol 17(5-6): 441-452 (2006).
11. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, et al. Broad-spectrum efficacy across cognitive domains by alpha 7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27(39): 10578-10587 (2007).
12. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacol 28(3): 542-551 (2003).
13. Chan WK, Wong PT-H, Sheu F-S. Frontal cortical alpha 7 and alpha 4 beta 2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacol 52(8): 1641-1649 (2007).
14. Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, et al. Discovery and structure - Activity relationship of quinuclidine benzamides as agonists of alpha 7 nicotinic acetylcholine receptors. J Med Chem 48(4): 905-908 (2005).
15. Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, et al. The selective alpha 7 nicotinic acetylcholine receptor agonist PNU-282987 N- (3R)-1-azabicyclo 2.2.2 oct-3-yl -4-chlorobenzamide hydrochloride enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312(3): 1213-1222 (2005).
16. Siok CJ, Rogers JA, Kocsis B, Hajos M. Activation of alpha 7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation. Eur J Neurosci 23(2): 570-574 (2006).
17. Vicens P, Ribes D, Torrente M, Domingo JL. Behavioral effects of PNU-282987, an alpha7 nicotinic receptor agonist, in mice. Behav Brain Res 216(1): 341-348 (2011).
18. Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic in the development of Alzheimer's disease. Neurosci Biobehav Rev 35(6): 1397-1409 (2011).
19. Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res 221(2): 334-340 (2011).
20. Bekris LM, Yu C-E, Bird TD, Tsuang DW. Genetics of Alzheimer Disease. J Geriatr Psych Neur 23(4): 213-227 (2010).
21. Schaeffer EL, Figueiro M, Gattaz WF. Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics 66: 45-54 (2011).
22. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 886(1-2): 172-189 (2000).
23. McEwen BS. Introduction - Protective and damaging effects of stress mediators: The good and bad sides of the response to stress. Metabolism 51(6): 2-4 (2002).
24. Ressler KJ. Amygdala Activity, Fear, and Anxiety: Modulation by Stress. Biol Psychiat 67(12):1117-1119 (2010).
25. Helm KA, Ziegler DR, Gallagher M. Habituation to stress and dexamethasone suppression in rats with selective basal forebrain cholinergic lesions. Hippocampus 14(5): 628-635 (2004).
26. Shao S-H, Shi S-S, Li Z-L, Zhao M-S, Xie S-Y, Pan F. Aging Effects on the BDNF mRNA and TrkB mRNA Expression of the Hippocampus in Different Durations of Stress. Chinese J Physiol 53(5):285-293 (2010).
27. Wang C, Wu H-m, Jing X-R, Meng Q, Liu B, Zhang H, et al. Oxidative Parameters in the Rat Brain of Chronic Mild Stress Model for Depression: Relation to Anhedonia-Like Responses. J Membr Biol 245(11): 675-681 (2012).
28. Petrik D, Lagace DC, Eisch AJ. The neurogenesis hypothesis of affective and anxiety disorders: Are we mistaking the scaffolding for the building? Neuropharmacology 62(1): 21-34 (2012).
29. Hofmann SG, Ellard KK, Siegle GJ. Neurobiological correlates of cognitions in fear and anxiety: A cognitive-neurobiological information-processing model. Cogn Emot 26(2): 282-299 (2012).
30. Obrien JT, Ames D, Schweitzer I, Colman P, Desmond P, Tress B. Clinical and magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in depression and Alzheimer's disease. Brit J Psychiat 168(6): 679-687 (1996).
31. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral Symptoms in Alzheimers-disease: Phenomenology and Treatment. J Clin Psychiat 48: 9-15 (1987).
32. Hunter RG. Stress and the alpha 7 Nicotinic Acetylcholine Receptor. Curr Drug Targets 13(5): 607-612 (2012).
33. Hunter RG, Bloss EB, McCarthy KJ, McEwen BS. Regulation of the nicotinic receptor alpha7 subunit by chronic stress and corticosteroids. Brain Res 1325: 141-146 (2010).
34. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17(6): 157-165 (2001).
35. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2): 159-170 (2004).
36. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APP(Swe)+PSEN1 Delta E9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 6(1): 54-65 (2007).
37. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MPF, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18(3): 602-617 (2005).
38. Wang HY, Lee DHS, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. Beta-amyloid(1-42) binds to alpha 7 nicotinic acetylcholine receptor with high affinity - Implications for Alzheimer's disease pathology. J Biol Chem 275(8): 5626-5632 (2000).
39. Wang H-Y, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P. Dissociating beta-Amyloid from alpha 7 Nicotinic Acetylcholine Receptor by a Novel Therapeutic Agent, S 24795, Normalizes alpha 7 Nicotinic Acetylcholine and NMDA Receptor Function in Alzheimer's Disease Brain. J Neurosci 29(35): 10961-10973 (2009).
40. Dineley KT. Beta-amyloid peptide - nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front Biosci 12: 5030-5038 (2007).
41. Parri RH, Dineley TK. Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 7(1):27-39 (2010).
42. Hernandez CM, Dineley KT. Alpha 7 Nicotinic Acetylcholine Receptors in Alzheimer's Disease: Neuroprotective, Neurotrophic or Both? Curr Drug Targets 13(5): 613-622 (2012).
43. Albina ML, Belles M, Linares V, Sanchez DJ, Domingo JL. Restraint stress does not enhance the uranium-induced developmental and behavioral effects in the offspring of uranium-exposed male rats. Toxicology 215(1-2): 69-79 (2005).
44. Colomina MT, Roig JL, Torrente M, Vicens P, Domingo JL. Concurrent exposure to aluminum and stress during pregnancy in rats: Effects on postnatal development and behavior of the offspring. Neurotoxicol Teratol 27(4): 565-574 (2005).
45. Fuentes S, Colomina MT, Rodriguez J, Vicens P, Domingo JL. Interactions in developmental toxicology: Concurrent exposure to perfluorooctane sulfonate (PFOS) and stress in pregnant mice. Toxicol Lett 164(1): 81-89 (2006).
46. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioral and pharmacological characterization of the elevated zero-maze as an animal-model of anxiety. Psychopharmacol 116(1): 56-64 (1994).
47. Kulkarni SK, Singh K, Bishnoi M. Elevated zero maze: A paradigm to evaluate antianxiety effects of drugs. Method Find Expl Clin 29(5): 343-348 (2007).
48. Aznar S, Knudsen GM. Depression and Alzheimer's Disease: Is Stress the Initiating Factor in a Common Neuropathological Cascade? J Alzheimers Dis 23: 177-193 (2011).
49. Gallagher D, Coen R, Kilroy D, Belinski K, Bruce I, Coakley D, et al. Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment. Int J Geriatr Psychiatry 26(2): 166-172 (2011).
50. Wilson RS, Begeny CT, Boyle PA, Schneider JA, Bennett DA. Vulnerability to Stress, Anxiety, and Development of Dementia in Old Age. Am J Geriatr Psychiatry 19(4): 327-334 (2011).
51. Taslim N, Soderstrom K, Dar MS. Role of mouse cerebellar nicotinic acetylcholine receptor (nAChR) alpha(4)beta(2)- and alpha(7) subtypes in the behavioral cross-tolerance between nicotine and ethanol-induced ataxia. Behav Brain Res 217(2): 282-292 (2011).
52. Shimohama S. Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models. Biol Pharm Bull 32(3): 332-336 (2009).
53. Clement Y, Joubert C, Kopp C, Lepicard EM, Venault P, Misslin R, et al. Anxiety in mice: a principal component analysis study. Neural Plast 2007: 35457 (2007).
54. Bouwknecht JA, Paylor R. Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behav Pharmacol 19(5-6): 385-402 (2008).
55. Marquez C, Nadal R, Armario A. The hypothalamic-pituitary-adrenal and glucose responses to daily repeated immobilisation stress in rats: Individual differences. Neuroscience 123(3): 601-612 (2004).
56. Uzun S, Kozumplik O, Folnegovic-Smalc V. Alzheimer's Dementia: Current Data Review. Collegium Antropol 35(4): 1333-1337 (2011).
57. Clement Y, Calatayud F, Belzung C. Genetic basis of anxiety-like behaviour: A critical review. Brain Res Bull 57(1): 57-71 (2002).
58. Clement Y, Le Guisquet A-M, Venault P, Chapouthier G, Belzung C. Pharmacological Alterations of Anxious Behaviour in Mice Depending on Both Strain and the Behavioural Situation. Plos One 4(11): A74-A81 (2009).